Another Study Identifies Actos Bladder Cancer Side Effects
A new study has linked Actos to bladder cancer. The study, published on July 3 in the Canadian Medical Association Journal, is the latest in a number of studies that have confirmed the link between Actos and bladder cancer.
In the study, researchers examined a number of biomedical databases, studies, and trials which included data on 2,657,365 patients. 3,643 of the patients studied had been diagnosed with bladder cancer.
According to the study, type 2 diabetes patients face a 22% increased risk of developing bladder cancer if they are taking Actos or a similar drug from the thiazolidinediones family of medications, which includes Avandia and Rezulin.
This research follows two other reports that were published a few weeks ago and that also confirm links between bladder cancer and Actos. In one study from the University of Pennsylvania, researchers determined that the problem may not be limited to Actos, but that it may be class-wide. However, a similar Canadian study linked the risk to only Actos.
The FDA began to study the link between Actos side effects and bladder cancer in September 2010. In 2011, a French insurance study was the first to positively report an Actos association. This study led to an Actos recall in France and Germany. In response to this data, the European Union and the United States (FDA) increased warnings on Actos labels but have yet to issue a recall.
Actos (pioglitazone) is made by Takeda Pharmaceuticals and was approved by the FDA for treatment of type 2 diabetes in July 1999. Drugs similar to Actos include ActoPlus Met and Duetact.
Contact an Actos Lawyer
A number of citizens who were diagnosed with bladder cancer after taking Actos have opted to file pharmaceutical product liability lawsuits for compensation. If you or someone you love has bladder cancer that may be linked to Actos, contact a dangerous drug lawyer for a free legal consultation.